Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study

Autor: Adrian M. Shields, Sian E. Faustini, Harriet J. Hill, Saly Al-Taei, Chloe Tanner, Fiona Ashford, Sarita Workman, Fernando Moreira, Nisha Verma, Hollie Wagg, Gail Heritage, Naomi Campton, Zania Stamataki, Mark T. Drayson, Paul Klenerman, James E. D. Thaventhiran, Shuayb Elkhalifa, Sarah Goddard, Sarah Johnston, Aarnoud Huissoon, Claire Bethune, Suzanne Elcombe, David M. Lowe, Smita Y. Patel, Sinisa Savic, Alex G. Richter, Siobhan O. Burns, the COV-AD consortium, Zahra Ahmed, Angus Best, Joanne Dasgin, Mohammad Dinally, Elena Efstathiou, Theresa McCarthy, Madeeha Hoque, Shannon Page, Timothy Plant, Zehra Suleiman, Neil Townsend, Charlotte Trinham, Sinead Walder, Hollie Bancroft, Michelle Bates, Hayley Clifford, Christopher McGee, Samuel Chee, Lucy Common, Archana Herwadkar, Karen Knowles, Maria Poulaka, Georgina Davis, Daniel Mullan, Stuart Wareham, Fatima Dhalla, Rashmi Jain, Hadeil Morsi, Nicholas Peters, Mark Gompels, Malgorzata Slowinsksa, Dan Hartland, Emily Heritage, Joe Humphreys, Deborah Hughes, Ann Ivory, Sinead Kelly, Eileen O’Grady, Archana Shajidevadas

Publikováno v: Frontiers in Immunology, Vol 13 (2022)

BackgroundPatients with primary and secondary antibody deficiency are vulnerable to COVID-19 and demonstrate diminished responses following two-dose SARS-CoV-2 vaccine schedules. Third primary vaccinations have been deployed to enhance their humoral

Externí odkaz: https://doaj.org/article/734129a987774428ad5c1764ee4dea11